Price To Earnings Ratio 108.59 | Sector PE 69.47 |
PB Ratio 15.92 | Sector PB 9.32 |
EPS 11.80 | Dividend Yield 0.00 |
Today's Volume 372.568 K | 5 Day Avg. Volume 379.235 K |
PEG Ratio -4.02 | Market Cap. ₹ 33,240.00 Cr. |
Time | SUVENPHAR | VS | Industry |
---|---|---|---|
1 Day | 1.13% | 0.19% | |
1 Week | 3.9% | 3.31% | |
1 Month | -2.61% | 0.92% | |
6 Months | 97.02% | 22.41% | |
1 Year | 83.72% | 48.28% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 1268.96 | Bullish |
20 | 1260.53 | Bullish |
30 | 1261.31 | Bullish |
50 | 1231.04 | Bullish |
100 | 1137.13 | Bullish |
200 | 928.1 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 358.48 | 457.20 | 330.00 | ||||
Investing Activities | -362.25 | -195.01 | -136.14 | ||||
Financing Activities | -13.80 | -241.95 | -156.48 | ||||
Net Cash Flow | -17.57 | 20.24 | 37.38 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Suven Pharmaceuticals | 1.13 | 3.9 | -2.61 | 97.02 | 83.72 |
Alembic | 1.66 | 6.55 | 4.98 | 2.76 | 2.76 |
Aurobindo Pharma | 0.39 | 3.15 | -9.87 | -7.14 | 16.99 |
Fortis Healthcare | 2.25 | 10.82 | 13.14 | 42.21 | 81.43 |
Ajanta Pharmaceuticals | 0.27 | -1.65 | -3.39 | 19 | 46.25 |
Suven Pharmaceuticals Limited is one of India’s leading contract development and manufacturing organisations (CDMOs). The company focuses on developing and manufacturing pharmaceutical ingredients and products for global innovator pharma companies. This blog will analyse Suven Pharmaceuticals' fundamentals to understand its financial health and growth prospects.
Suven Pharmaceuticals is an Indian pharmaceutical company founded in 1989 by Mr. Jasti Venkateswarlu and Mrs. Jasti Sudha Rani. The company started by manufacturing bulk drugs and drug intermediates. Over the years, Suven has evolved into a major CDMO player serving global pharmaceutical and biotech companies.
The company operates through two business verticals – Contract Research and Manufacturing Services (CRAMS) and Specialty Chemicals. Under CRAMS, Suven provides end-to-end contract research, manufacturing, and supply services for pharmaceutical companies’ proprietary products. The Specialty Chemicals division manufactures and supplies speciality chemicals to various industrial sectors.
Suven has a global presence with manufacturing facilities in India, a formulation facility in the US, and offices in the UK, China, and South Africa. The company is listed on the National Stock Exchange and Bombay Stock Exchange in India.
As of date, Suven Pharma's share price was trading at ₹634.50.
The global pharmaceutical market is expected to reach nearly $2 trillion by 2027, exhibiting a CAGR of 6% over 2020-2027. Key growth factors include a rising old population, increasing prevalence of chronic diseases, healthcare spending, and higher consumer spending power.
India’s pharmaceutical market is the third largest globally in terms of volume and 11th in terms of value. It is projected to grow at a 9-11% CAGR over the next five years and reach $65 billion by 2025.
The high growth potential makes the pharmaceutical industry attractive for investments. Leading Indian pharma companies have benefitted from increased outsourcing by global majors over the years. The CRAMS market in India reached nearly $18 billion in FY21.
As one of the leading CDMO players, Suven Pharma is well-positioned to leverage the growing opportunity in contract services and speciality chemicals. Suven Life Sciences share price, strong track record, global access and cost competitiveness make it an attractive investment option.
Some of Suven’s major competitors in the CDMO space include:
Suven enjoys competitive advantages like strong client relationships, compliance standards, diverse service offerings and cost efficiencies. However, competition has intensified as more players enter the contract services space.
Suven Pharmaceuticals Limited has over 30 years of operating history marked by several key milestones:
Through strategic expansions, partnerships and patents over the years, Suven has evolved into an industry leading CDMO player with global operations.
Financial Metric |
Value |
---|---|
₹ 16,155 Cr. |
|
Book Value |
₹ 76.0 |
0.16% |
|
32.5% |
|
₹ 1.00 |
|
24.5% |
Here’s the shareholding pattern of Suven Pharmaceuticals Limited:
Overall, Suven has a healthy mix of promoters and institutional and public shareholders. The shareholding pattern demonstrates the company's positive investment appeal for both domestic and foreign investors.
*The shareholding data is as of March 2024 and may change over time.
Stock |
ROCE % |
||
---|---|---|---|
Suven Pharma |
43.56 |
32.47 |
0.16 |
Sun Pharma |
35.10 |
17.31 |
0.77 |
Cipla |
28.05 |
23.08 |
0.57 |
Dr. Reddy’s Labs |
17.52 |
26.86 |
0.68 |